Yes, and i can't help but notice that the CEO over there follows Prescient on Linkedin. Its been mentioned several times that CellPryme can be applied to both T and NK cells (among others). Its non-disruptive, and its the uncomplicated nature of the technology (offering a beneficial helping hand) akin to CHM's Core-NK platform that I like. Both CellPryme and CORE-NK have plenty of merit for nearer-term monetisation in my view.
The industry is striving to achieve lower cell-manufacturing costs, increased potency and durability of immunotherapies because immunotherapy works but can be improved.
Yes, and i can't help but notice that the CEO over there follows...
Add to My Watchlist
What is My Watchlist?
